Back-view of a man in a blue polo gazing at a forested mountain

Scientific Evidence

Clinical evidence and peer reviewed studies

TissueCypher is supported by 13 published clinical validation and utility studies that encompass one of the largest sets of Barrett's esophagus (BE) progressor patients ever assembled. In these studies, TissueCypher consistently outperforms histology and segment length as predictors of progression.

Discover More

  • A randomized controlled study on clinical adherence to evidence-based guidelines in the management of simulated patients with Barrett’s esophagus and the clinical utility of a tissue systems pathology test: results from Q-TAB

    12 Jan 2024

    TissueCypher optimized adherence to clinical guidelines for surveillance and treatment of both BE patients at high and low risk for disease progression. Use of the test can enable physicians to make risk-aligned management decisions, leading to improved patient health outcomes.  

    Peabody JW, et al.

  • An Automated Tissue Systems Pathology Test Can Standardize the Management and Improve Health Outcomes for Patients with Barrett's Esophagus

    01 Nov 2023

    Management guided by the TissueCypher test can standardize care plans by increasing the early detection of progressors who can receive therapeutic interventions, while also increasing the percentage of nonprogressors who can avoid unnecessary therapy and be managed by surveillance alone.

    Duits, Lucas C, et al.

  • A Tissue Systems Pathology Test Outperforms the Standard of Care Variables in Predicting Progression in Patients with Barrett’s Esophagus

    01 Nov 2023

    This study evaluated the predictive performance of TissueCypher versus current clinicopathologic variables in a multi-center cohort of BE patients.

    Davison JM, et al.

  • The Tissue Systems Pathology Test Outperforms Pathology Review in Risk-Stratifying Patients with Low-Grade Dysplasia

    01 Nov 2023

    This study aimed to compare the risk stratification performance of the TissueCypher test vs benchmarks of generalist and expert pathology.

    Khoshiwal AM, et al.

  • A Tissue Systems Pathology Test Enables Risk-Aligned Management of Patients with Non-Dysplastic Barrett’s Esophagus: Case Reports from a Gastrointestinal Surgery Center

    25 Sep 2023

    TissueCypher demonstrated clinical utility in NDBE patients by guiding risk-aligned upstaging of care and potential improved health outcomes in BE patients.

    Tseng D, et al.

Click to learn more
next up

Order Process & Results

View More